Lupin gets approval from USFDA for Paliperidone Extended-Release Tablets

Lupin gets approval from USFDA for Paliperidone Extended-Release Tablets

by admin- Friday, July 1st, 2022 04:27:45 PM

Global pharma major Lupin introduced that it has acquired approval from america Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA), Paliperidone Extended-Release Tablets 1.5 mg, 3 mg, 6 mg, and 9 mg, to market a well-known equivalent of Invega® Extended-Release Tablets, 1.Five mg, three mg, 6 mg, and nine mg, of Janssen Research and Development, LLC. The product may be synthetic at Lupin’s facility in Goa, India.

Paliperidone Extended-Release Tablets had envisioned annual income of USD 152 million inside the US.

News Updates